In line with this notion, Llosa et al recently identified a cluster of about 10% of MSS patients characterized by elevated PD1+Tc1 cells, elevated PD‐L1 expression, and diminished IL‐17+ T cells, which showed significant response to anti‐PD‐1 monotherapy [51]. This evidence concerns the gene IL17A and Marinesco-Sjogren syndrome.